DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice

Ayako Ojima, Takanori Matsui, Sayaka Maeda, Masayoshi Takeuchi, Hiroyoshi Inoue, Yuichiro Higashimoto, Sho Ichi Yamagishi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced glycation end products (AGE-aptamer) inhibited melanoma growth in nude mice. G361 melanoma cells were injected intradermally into the upper flank of athymic nude mice. Mice received continuous intraperitoneal infusion (0.136 μg/day) of either AGE-aptamer (n=9) or Control-aptamer (n=8) by an osmotic mini pump. Tumor volume was measured at 4-day interval, and G361 melanoma was excised at day 43 after the aptamer treatment. We further examined the effects of AGE-aptamer on proliferation of AGE-exposed endothelial cells and G361 cells. AGE-aptamer significantly inhibited the in vivo-tumor growth of G361 melanoma. Immunohistochemical and western blotting analyses of G361 melanoma revealed that AGE-aptamer decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. AGE-aptamer significantly decreased the number of tumor-associated vessels. AGE, receptor for AGE (RAGE) and vascular endothelial growth factor levels were also reduced in AGE-aptamer-treated G361 melanoma. AGE-aptamer inhibited the AGE-induced proliferation and tube formation of endothelial cells as well as the growth of G361 cells in vitro. The present findings suggest that AGE-aptamer could inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes.

Original languageEnglish
Pages (from-to)422-429
Number of pages8
JournalLaboratory Investigation
Volume94
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Nucleotide Aptamers
Advanced Glycosylation End Products
Nude Mice
Melanoma
Growth
Endothelial Cells
Neoplasms
Parenteral Infusions
Nuclear Antigens
Tumor Burden
Vascular Endothelial Growth Factor A
Epidemiologic Studies
Western Blotting
Macrophages

Keywords

  • AGE
  • aptamer
  • diabetes
  • melanoma
  • RAGE

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. / Ojima, Ayako; Matsui, Takanori; Maeda, Sayaka; Takeuchi, Masayoshi; Inoue, Hiroyoshi; Higashimoto, Yuichiro; Yamagishi, Sho Ichi.

In: Laboratory Investigation, Vol. 94, No. 4, 2014, p. 422-429.

Research output: Contribution to journalArticle

Ojima, A, Matsui, T, Maeda, S, Takeuchi, M, Inoue, H, Higashimoto, Y & Yamagishi, SI 2014, 'DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice', Laboratory Investigation, vol. 94, no. 4, pp. 422-429. https://doi.org/10.1038/labinvest.2014.5
Ojima, Ayako ; Matsui, Takanori ; Maeda, Sayaka ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Higashimoto, Yuichiro ; Yamagishi, Sho Ichi. / DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. In: Laboratory Investigation. 2014 ; Vol. 94, No. 4. pp. 422-429.
@article{4aab5f2c820346faacd8842404e98421,
title = "DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice",
abstract = "Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced glycation end products (AGE-aptamer) inhibited melanoma growth in nude mice. G361 melanoma cells were injected intradermally into the upper flank of athymic nude mice. Mice received continuous intraperitoneal infusion (0.136 μg/day) of either AGE-aptamer (n=9) or Control-aptamer (n=8) by an osmotic mini pump. Tumor volume was measured at 4-day interval, and G361 melanoma was excised at day 43 after the aptamer treatment. We further examined the effects of AGE-aptamer on proliferation of AGE-exposed endothelial cells and G361 cells. AGE-aptamer significantly inhibited the in vivo-tumor growth of G361 melanoma. Immunohistochemical and western blotting analyses of G361 melanoma revealed that AGE-aptamer decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. AGE-aptamer significantly decreased the number of tumor-associated vessels. AGE, receptor for AGE (RAGE) and vascular endothelial growth factor levels were also reduced in AGE-aptamer-treated G361 melanoma. AGE-aptamer inhibited the AGE-induced proliferation and tube formation of endothelial cells as well as the growth of G361 cells in vitro. The present findings suggest that AGE-aptamer could inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes.",
keywords = "AGE, aptamer, diabetes, melanoma, RAGE",
author = "Ayako Ojima and Takanori Matsui and Sayaka Maeda and Masayoshi Takeuchi and Hiroyoshi Inoue and Yuichiro Higashimoto and Yamagishi, {Sho Ichi}",
year = "2014",
doi = "10.1038/labinvest.2014.5",
language = "English",
volume = "94",
pages = "422--429",
journal = "Laboratory investigation; a journal of technical methods and pathology",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice

AU - Ojima, Ayako

AU - Matsui, Takanori

AU - Maeda, Sayaka

AU - Takeuchi, Masayoshi

AU - Inoue, Hiroyoshi

AU - Higashimoto, Yuichiro

AU - Yamagishi, Sho Ichi

PY - 2014

Y1 - 2014

N2 - Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced glycation end products (AGE-aptamer) inhibited melanoma growth in nude mice. G361 melanoma cells were injected intradermally into the upper flank of athymic nude mice. Mice received continuous intraperitoneal infusion (0.136 μg/day) of either AGE-aptamer (n=9) or Control-aptamer (n=8) by an osmotic mini pump. Tumor volume was measured at 4-day interval, and G361 melanoma was excised at day 43 after the aptamer treatment. We further examined the effects of AGE-aptamer on proliferation of AGE-exposed endothelial cells and G361 cells. AGE-aptamer significantly inhibited the in vivo-tumor growth of G361 melanoma. Immunohistochemical and western blotting analyses of G361 melanoma revealed that AGE-aptamer decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. AGE-aptamer significantly decreased the number of tumor-associated vessels. AGE, receptor for AGE (RAGE) and vascular endothelial growth factor levels were also reduced in AGE-aptamer-treated G361 melanoma. AGE-aptamer inhibited the AGE-induced proliferation and tube formation of endothelial cells as well as the growth of G361 cells in vitro. The present findings suggest that AGE-aptamer could inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes.

AB - Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced glycation end products (AGE-aptamer) inhibited melanoma growth in nude mice. G361 melanoma cells were injected intradermally into the upper flank of athymic nude mice. Mice received continuous intraperitoneal infusion (0.136 μg/day) of either AGE-aptamer (n=9) or Control-aptamer (n=8) by an osmotic mini pump. Tumor volume was measured at 4-day interval, and G361 melanoma was excised at day 43 after the aptamer treatment. We further examined the effects of AGE-aptamer on proliferation of AGE-exposed endothelial cells and G361 cells. AGE-aptamer significantly inhibited the in vivo-tumor growth of G361 melanoma. Immunohistochemical and western blotting analyses of G361 melanoma revealed that AGE-aptamer decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. AGE-aptamer significantly decreased the number of tumor-associated vessels. AGE, receptor for AGE (RAGE) and vascular endothelial growth factor levels were also reduced in AGE-aptamer-treated G361 melanoma. AGE-aptamer inhibited the AGE-induced proliferation and tube formation of endothelial cells as well as the growth of G361 cells in vitro. The present findings suggest that AGE-aptamer could inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes.

KW - AGE

KW - aptamer

KW - diabetes

KW - melanoma

KW - RAGE

UR - http://www.scopus.com/inward/record.url?scp=84897388063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897388063&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2014.5

DO - 10.1038/labinvest.2014.5

M3 - Article

C2 - 24514068

AN - SCOPUS:84897388063

VL - 94

SP - 422

EP - 429

JO - Laboratory investigation; a journal of technical methods and pathology

JF - Laboratory investigation; a journal of technical methods and pathology

SN - 0023-6837

IS - 4

ER -